SETTLEMENT AGREEMENTSettlement Agreement • February 27th, 2020 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This Settlement Agreement (hereinafter, “Agreement”) is made and entered into as of the 9th day of December 2019, by and between Defendant Momenta Pharmaceuticals, Inc. (“Defendant”), and Plaintiffs, both individually and on behalf of the Class in the above-captioned class action. This Agreement is intended by the Settling Parties to fully, finally and forever resolve, discharge and settle the Released Claims, upon and subject to the terms and conditions hereof.
AMENDMENT NO. 6 to the COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • February 27th, 2020 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances)
This Amendment No. 6 (this “Amendment No. 6”) to the Collaboration and License Agreement (the “Agreement”) by and between Sandoz AG, a Swiss corporation with offices located at Lichtstraβe 35, CH 4056 Basel BS, Switzerland (“Sandoz”) and Momenta Pharmaceuticals, Inc., a Delaware company with offices located at 301 Binney Street, Cambridge, MA 02142 U.S.A. (“Momenta”) is made effective as of November 30, 2018 (the “Amendment No. 6 Effective Date”). Sandoz and Momenta may hereafter be referred to collectively as the “Parties” and individually as a “Party”.
